107 related articles for article (PubMed ID: 20100577)
1. Expression, purification and biochemical characterization of the N-terminal regions of human TIG3 and HRASLS3 proteins.
Han BG; Cho JW; Cho YD; Kim SY; Yoon HJ; Song HK; Cheong HK; Jeon YH; Lee DK; Lee S; Lee BI
Protein Expr Purif; 2010 May; 71(1):103-7. PubMed ID: 20100577
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the human tumor suppressors TIG3 and HRASLS2 as phospholipid-metabolizing enzymes.
Uyama T; Jin XH; Tsuboi K; Tonai T; Ueda N
Biochim Biophys Acta; 2009 Dec; 1791(12):1114-24. PubMed ID: 19615464
[TBL] [Abstract][Full Text] [Related]
3. Structural and functional characterization of tumor suppressors TIG3 and H-REV107.
Wei H; Wang L; Ren X; Yu W; Lin J; Jin C; Xia B
FEBS Lett; 2015 May; 589(11):1179-86. PubMed ID: 25871522
[TBL] [Abstract][Full Text] [Related]
4. Pericentrosomal localization of the TIG3 tumor suppressor requires an N-terminal hydrophilic region motif.
Scharadin TM; Adhikary G; Shaw K; Grun DJB; Xu W; Eckert RL
J Invest Dermatol; 2014 May; 134(5):1220-1229. PubMed ID: 24401997
[TBL] [Abstract][Full Text] [Related]
5. The carboxy-terminal hydrophobic domain of TIG3, a class II tumor suppressor protein, is required for appropriate cellular localization and optimal biological activity.
Deucher A; Nagpal S; Chandraratna RA; Di Sepio D; Robinson NA; Dashti SR; Eckert RL
Int J Oncol; 2000 Dec; 17(6):1195-203. PubMed ID: 11078805
[TBL] [Abstract][Full Text] [Related]
6. Localization of the TIG3 transglutaminase interaction domain and demonstration that the amino-terminal region is required for TIG3 function as a keratinocyte differentiation regulator.
Jans R; Sturniolo MT; Eckert RL
J Invest Dermatol; 2008 Mar; 128(3):517-29. PubMed ID: 17762858
[TBL] [Abstract][Full Text] [Related]
7. Solution structure of the N-terminal catalytic domain of human H-REV107--a novel circular permutated NlpC/P60 domain.
Ren X; Lin J; Jin C; Xia B
FEBS Lett; 2010 Oct; 584(19):4222-6. PubMed ID: 20837014
[TBL] [Abstract][Full Text] [Related]
8. 1H, 13C, and 15N resonance assignments of the N-terminal domain of human TIG3.
Wang L; Yu W; Ren X; Lin J; Jin C; Xia B
Biomol NMR Assign; 2012 Oct; 6(2):201-3. PubMed ID: 22290676
[TBL] [Abstract][Full Text] [Related]
9. The tumor suppressor gene H-Rev107 functions as a novel Ca2+-independent cytosolic phospholipase A1/2 of the thiol hydrolase type.
Uyama T; Morishita J; Jin XH; Okamoto Y; Tsuboi K; Ueda N
J Lipid Res; 2009 Apr; 50(4):685-93. PubMed ID: 19047760
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene.
DiSepio D; Ghosn C; Eckert RL; Deucher A; Robinson N; Duvic M; Chandraratna RA; Nagpal S
Proc Natl Acad Sci U S A; 1998 Dec; 95(25):14811-5. PubMed ID: 9843971
[TBL] [Abstract][Full Text] [Related]
11. A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase.
Sturniolo MT; Dashti SR; Deucher A; Rorke EA; Broome AM; Chandraratna RA; Keepers T; Eckert RL
J Biol Chem; 2003 Nov; 278(48):48066-73. PubMed ID: 12928434
[TBL] [Abstract][Full Text] [Related]
12. Cloning and characterization of a novel retinoid-inducible gene 1(RIG1) deriving from human gastric cancer cells.
Huang SL; Shyu RY; Yeh MY; Jiang SY
Mol Cell Endocrinol; 2000 Jan; 159(1-2):15-24. PubMed ID: 10687848
[TBL] [Abstract][Full Text] [Related]
13. Phospholipase A/Acyltransferase enzyme activity of H-rev107 inhibits the H-RAS signaling pathway.
Wang CH; Shyu RY; Wu CC; Tsai TC; Wang LK; Chen ML; Jiang SY; Tsai FM
J Biomed Sci; 2014 May; 21(1):36. PubMed ID: 24884338
[TBL] [Abstract][Full Text] [Related]
14. TIG3 tumor suppressor-dependent organelle redistribution and apoptosis in skin cancer cells.
Scharadin TM; Jiang H; Jans R; Rorke EA; Eckert RL
PLoS One; 2011; 6(8):e23230. PubMed ID: 21858038
[TBL] [Abstract][Full Text] [Related]
15. 1H, 13C and 15N resonance assignments of human H-REV107 N-terminal domain.
Ren X; Lin J; Jin C; Xia B
Biomol NMR Assign; 2010 Oct; 4(2):175-8. PubMed ID: 20526701
[TBL] [Abstract][Full Text] [Related]
16. Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype.
Higuchi E; Chandraratna RA; Hong WK; Lotan R
Oncogene; 2003 Jul; 22(30):4627-35. PubMed ID: 12879006
[TBL] [Abstract][Full Text] [Related]
17. Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and -independent mechanisms.
Lotz K; Kellner T; Heitmann M; Nazarenko I; Noske A; Malek A; Gontarewicz A; Schäfer R; Sers C
Int J Cancer; 2005 Oct; 116(6):894-902. PubMed ID: 15856468
[TBL] [Abstract][Full Text] [Related]
18. LRAT-specific domain facilitates vitamin A metabolism by domain swapping in HRASLS3.
Golczak M; Sears AE; Kiser PD; Palczewski K
Nat Chem Biol; 2015 Jan; 11(1):26-32. PubMed ID: 25383759
[TBL] [Abstract][Full Text] [Related]
19. Ameliorating effect of lipo-ATRA treatment on the expression of TIG3 and its suppressing effect on PPARγ gene expression in lung cancer animal model.
Ravichandran R; Viswanathan S; Berlin Grace VM; Bonati L; Narayanan J
Mol Cell Biochem; 2019 Oct; 460(1-2):105-112. PubMed ID: 31300983
[TBL] [Abstract][Full Text] [Related]
20. A novel transglutaminase activator forms a complex with type 1 transglutaminase.
Sturniolo MT; Chandraratna RA; Eckert RL
Oncogene; 2005 Apr; 24(18):2963-72. PubMed ID: 15846304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
